No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas

Karen T. Barker, Hayley E. Spendlove, Nassera S. Banu, Julia A. Bridge, Cyril Fisher, Janet Shipley, Michelle Garrett, Isaac Manyonda, Richard S. Houlston

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Germline mutations in Fumarate Hydratase (FH) cause the development of leiomyomas and leiomyosarcomas in the syndromes Multiple Cutaneous and Uterine Leiomyomata (MCUL1) and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). There is little evidence, however, that FH mutation plays a role in the development of sporadic leiomyomas or leiomyosarcomas. Such observations do not, however, exclude a role for FH in tumour development outside the context of MCUL1/HLRCC, as it is possible that FH expression could be silenced by epigenetic mechanisms. To explore this possibility we have developed a highly specific antibody to FH and analysed a series of forty-five fresh-frozen uterine leiomyomas and nine leiomyosarcomas for FH expression.

Original languageEnglish (US)
Pages (from-to)136-140
Number of pages5
JournalCancer Letters
Volume235
Issue number1
DOIs
StatePublished - Apr 8 2006

Keywords

  • Fumarate hydratase
  • Leiomyoma
  • Leiomyosarcoma
  • Western blotting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas'. Together they form a unique fingerprint.

  • Cite this

    Barker, K. T., Spendlove, H. E., Banu, N. S., Bridge, J. A., Fisher, C., Shipley, J., Garrett, M., Manyonda, I., & Houlston, R. S. (2006). No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. Cancer Letters, 235(1), 136-140. https://doi.org/10.1016/j.canlet.2005.04.017